Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.

BMC cancer - 18 Feb 2015

Wheler Jennifer, Yelensky Roman, Falchook Gerald, Kim Kevin B, Hwu Patrick, Tsimberidou Apostolia M, Stephens Philip J, Hong David, Cronin Maureen T, Kurzrock Razelle

Abstract excerpt

BACKGROUND: Patients with BRAF mutation-positive advanced melanoma respond well to matched therapy with BRAF or MEK inhibitors, but often quickly develop resistance. METHODS: Tumor tissue from ten patients with advanced BRAF mutation-positive melanoma who achieved partial response (PR) or complete response (CR) on BRAF and/or MEK inhibitors was analyzed using next generation sequencing (NGS) assay. Genomic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Neoplasm
Share to High-Throughput Nucleotide Sequencing

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Pilot Projects

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 25886620
DOI: 10.1186/s12885-015-1029-z
PMCID: PMC4340232

Genes

BRAF
APC
ATM
MET
MITF
MYC
NRAS
PAX5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.PMID 25886620Read ↗

Next-Generation Sequencing Reveals Pathway Activations and New Routes to Targeted Therapies in Cutaneous Metastatic Melanoma.Semantic proximity Read ↗

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing-Based Panel to BRAF Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies.Semantic proximity Read ↗

Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.Semantic proximity Read ↗

Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like CellsSemantic proximity Read ↗

Somatic mutation analysis in melanoma using targeted next generation sequencing.Semantic proximity Read ↗

A Melanoma-Tailored Next-Generation Sequencing Panel Coupled with a Comprehensive Analysis to Improve Routine Melanoma Genotyping.Semantic proximity Read ↗

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib–treated Patients with BRAF V600-mutated Metastatic MelanomaSemantic proximity Read ↗

Detecting mechanisms of acquired BRAF inhibitor resistance in melanoma.Semantic proximity Read ↗

Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles.Semantic proximity Read ↗

Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.Semantic proximity Read ↗

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.